Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXI-001 in Relapsed AML or MDS Post-HCT
NCT04284228Phase 2Active, not recruiting
- Sponsor
- NexImmune, Inc.
- Start
- Feb 2020
- Primary completion
- Oct 2024
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NEXI-001 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by NexImmune, Inc.. Started Feb 2020; status: active, not recruiting.
02
Drugs
NEXI-001
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04284228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284228.